Payment processing for the peptide lab running 5 research-chem brands
- Peptide brands have a 4-9 month lifespan on Stripe before a freeze. It is not a question of if.
- Running 5 brands gives you resilience if the processor stack is designed for it; running 5 brands on 5 Stripes gives you 5 freeze events.
- Crypto, Zelle, Venmo workarounds work temporarily and wreck your conversion. The real answer is a specialist acquirer with known underwriting for peptides.
On this page
You manufacture or source peptides. You sell them through 5 consumer-facing brands, each with its own domain, aesthetic, and customer segment. Combined monthly volume runs $200k-$1.5M. You have survived at least one processor freeze already. You are still running a mix of makeshift stacks because no processor has stayed live for all 5 brands at once for more than a year.
Your stack today
Some version of: 2 brands on a specialist high-risk processor (EasyPayDirect, Corepay, PayKings, Durango, or similar). 1 brand running Zelle plus a Square "personal training services" workaround that is one dispute from being terminated. 1 brand accepts only crypto because it got banned from cards 6 months ago. 1 brand is on a fresh Stripe account set up under a spouse's name and EIN that you know is not compliant.
Fulfillment is a single warehouse shipping for all 5 brands. Tracking numbers are distinct per brand but the warehouse is obviously the same and card networks can tell. Your Shopify stores each run on a different template and you spent time making them look unrelated.
Customer support is one inbox per brand, same human behind all of them. COA documents are hosted on each site. Your reality is that every brand looks like a peptide brand to anyone who looks for more than 60 seconds, and that is the underwriting problem.
Your pain points
- Running 5 parallel processor relationships. Each with its own reserve schedule, payout timing, support queue, dispute portal. You or your ops person spend 10-15 hours a week on payments alone.
- Conversion collapse on the crypto-only brand. You know it loses 60-75% of would-be buyers at checkout. You keep it running because at least it processes.
- Zelle/Venmo workaround is a legal and operational nightmare. P2P payment rails are not for commerce. You are violating ToS. Customers dispute by calling the bank.
- Reserves tie up 20-35% of your cash. Across 5 specialist processors you have 6 figures parked as reserve, sometimes held 180 days or longer.
- Descriptor inconsistency drives disputes. Customers see "EPD * LAB B XYZ" and have no idea what it is. Dispute rates run 1.8-3%, permanently on the edge of card network monitoring.
- New brand launches take 8-12 weeks because the specialist ISO requires full underwriting on each new DBA.
- No single source of truth for revenue, fees, refunds, or chargebacks. Month-end close is a 3-day spreadsheet project.
Why peptide portfolios get frozen
Peptides are not illegal, but they are unambiguously in card brand prohibited-content territory when sold for "research use only" to retail consumers. Visa and Mastercard both flag SKUs like BPC-157, TB-500, GHK-Cu, CJC-1295, Ipamorelin, Melanotan, and any of the GLP-1 analogs as high-review.
Stripe, Square, PayPal, and Shopify Payments have explicit policy language prohibiting research chemicals including peptides. They use automated content scrapers against your product pages. You are not being singled out; you are being caught by a content classifier that runs continuously.
Specialist high-risk ISOs will underwrite you, but they are more cautious than they were in 2022-2023. Reserves went from 5-10% to 10-20%. Onboarding went from 2 weeks to 6-8. Some ISOs exited peptides entirely after Visa's 2024 policy clarification.
The bigger structural risk: when one of your 5 brands has a bad month, the specialist ISO may terminate not just that brand but every related brand under the same ownership. They check beneficial owners. If you are the sole member of 5 LLCs, losing one often means losing all.
What multiflow does for you
We run a purpose-built parent acquirer relationship for peptide portfolios. Single underwriting of you as the operator, single reserve, brand-level descriptors for all 5 brands. Offshore acquiring routing for cards that US acquirers refuse. Crypto as a fallback tier, not the primary.
Specifically:
- One specialist acquirer that has processed peptides continuously since 2019 and has a live book of $400M+ in the vertical.
- All 5 brands under one MID hierarchy with distinct descriptors. Cross-contamination risk eliminated.
- Reserve set at portfolio level, typically 8-12%, in writing, 90-day rolling. Not changeable without notice.
- Chargeback defense desk: automated representments, compelling-evidence kits specific to peptide disputes, dispute-win rates 35-45% (industry average is 12-20%).
- Payment methods beyond cards: ACH, Zelle (via a proper merchant-Zelle gateway not P2P), crypto as optional tier, Apple Pay and Google Pay where approved.
- New brand addition: 7-14 days from signed addendum to live descriptor. No full new underwriting.
- Consolidated reporting with per-brand P&L, per-SKU chargeback rates, per-customer lifetime value across brands.
The rate you would lock in
Peptide portfolios are priced with full transparency about the risk. Rate: 7.0-8.5% per transaction plus interchange passthrough, plus one-time setup fee. At $1M+/mo across the portfolio you drop to 6.5-7.5%. Reserves 8-12%. ACH 1.2% capped $25. Zelle-merchant 0.6%.
Is this cheaper than your current stack? Usually yes, once you add up specialist ISO rates (typically 5-6.5% per brand) plus the opportunity cost of Zelle/crypto (60-75% conversion loss on one brand), plus reconciliation overhead. Run the numbers in the application.